Related Experiment Video
Updated: Mar 25, 2026

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
Published on: March 23, 2016
EZOGABINE (POTIGA) MACULOPATHY
Brian E Zaugg1, James E Bell, Kim Y Taylor
1Department of Ophthalmology and Visual Sciences, Moran Eye Center, University of Utah Health Sciences Center, Salt Lake City, Utah.
Purpose:
To present a case of partially reversible retinal toxicity related to a newer epilepsy medication, ezogabine (Potiga).
Methods:
Case report with multimodal imaging.
Patient:
A patient presented 9 months after starting ezogabine for a screening eye examination with new retinal pigment abnormalities in the maculas of both eyes.
Results:
These macular abnormalities are characterized for the first time with multimodal imaging. They were partially reversible after cessation of the drug.
Conclusion:
Ezogabine toxicity presents as pigmentary changes in the macula on fundus examination and has newly described characteristics on imaging that can guide ophthalmologists when they perform the FDA-recommended 6-month screening visits for ocular toxicity.
More Related Videos
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
07:04Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Published on: February 4, 2021
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview
Angle Closure Glaucoma: Treatment